Johnson Pharmacare (532154) Q4 22/23 earnings summary

Executive summary

• FY23 revenue from operations was Rs 252.69 lakh, while expenses of Rs 385.62 lakh drove a net loss of Rs 129.14 lakh; FY22 recorded net profit of Rs 9.67 lakh.

• Operations were constrained by scarce working capital; management said it was seeking an opportunity to restart activity and had undertaken cost-reduction measures.

Financial highlights

• Revenue from operations fell to Rs 252.69 lakh from Rs 326.32 lakh YoY; total expenses rose to Rs 385.62 lakh from Rs 312.89 lakh.

• Other expenses reached Rs 176.26 lakh versus Rs 34.12 lakh, including a Rs 155.20 lakh loss on sale of shares.

• Loss before tax was Rs 132.93 lakh; after-tax loss was Rs 129.14 lakh, versus FY22 profit before tax of Rs 13.44 lakh and net profit of Rs 9.67 lakh.

• Cash and cash equivalents were Rs 0.18 lakh at year-end, down from Rs 4.06 lakh; total assets were Rs 5,983.02 lakh versus Rs 5,998.06 lakh.

Outlook and guidance

• Future development depends on restarting operational activities; management was looking for a suitable opportunity to make operations active and pursuing feasible cost reductions.